Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents.
作者信息
Foxwell B, Andreakos E, Brennan F, Feldmann M, Smith C, Conron M
机构信息
The Kennedy Institute of Rheumatology Division, Imperial College London, The Charing Cross Campus, ARC Building, 1 Aspenlea Road, London W6 8LH, UK.
出版信息
Ann Rheum Dis. 2003 Nov;62 Suppl 2(Suppl 2):ii90-3. doi: 10.1136/ard.62.suppl_2.ii90.
Abstract
摘要
相似文献
1
Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents.开发小分子化合物以替代抗肿瘤坏死因子生物制剂的前景。
Ann Rheum Dis. 2003 Nov;62 Suppl 2(Suppl 2):ii90-3. doi: 10.1136/ard.62.suppl_2.ii90.
2
Design and synthesis of orally active inhibitors of TNF synthesis as anti-rheumatoid arthritis drugs.作为抗类风湿性关节炎药物的肿瘤坏死因子合成口服活性抑制剂的设计与合成。
Bioorg Med Chem Lett. 2003 Nov 17;13(22):3951-4. doi: 10.1016/j.bmcl.2003.08.076.
3
Anti-cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis treated with anti-tumour necrosis factor agents.接受抗肿瘤坏死因子药物治疗的类风湿关节炎患者中的抗环瓜氨酸肽抗体
Ann Rheum Dis. 2005 Dec;64(12):1807. doi: 10.1136/ard.2005.040436.
4
Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe.类风湿关节炎中抗肿瘤坏死因子治疗起始指南：欧洲各地的异同
Ann Rheum Dis. 2009 Apr;68(4):456-9. doi: 10.1136/ard.2008.100362.
5
Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again).再次更新英国风湿病学会关于成人类风湿关节炎抗肿瘤坏死因子治疗的指南。
Rheumatology (Oxford). 2006 Jun;45(6):649-52. doi: 10.1093/rheumatology/kel053. Epub 2006 Mar 9.
6
When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?当类风湿性关节炎患者对肿瘤坏死因子抑制剂治疗无效时：下一步该怎么做？
Ann Rheum Dis. 2008 Nov;67(11):1497-8. doi: 10.1136/ard.2008.098111.
7
[Effectiveness and safety of the treatment with tumour necrosis factor alpha antagonists in rheumatoid arthritis patients].[肿瘤坏死因子α拮抗剂治疗类风湿关节炎患者的有效性和安全性]
Med Clin (Barc). 2005 Jun 4;125(1):35-6. doi: 10.1157/13076403.
8
Differential drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.类风湿关节炎中对抗肿瘤坏死因子药物的差异耐药性
Ann Rheum Dis. 2006 Jun;65(6):701-3. doi: 10.1136/ard.2005.049890.
9
Anti-tumour necrosis factor alpha therapy modulates ghrelin in patients with severe rheumatoid arthritis.抗肿瘤坏死因子α疗法可调节重度类风湿关节炎患者的胃饥饿素。
Ann Rheum Dis. 2008 Nov;67(11):1644-6. doi: 10.1136/ard.2008.088773.
10
Anti-tumour necrosis factor {alpha} therapy in patients with rheumatoid arthritis results in a significant and long-lasting decrease of concomitant glucocorticoid treatment.类风湿关节炎患者接受抗肿瘤坏死因子α治疗后，同时使用的糖皮质激素治疗量显著且持久减少。
Ann Rheum Dis. 2009 Dec;68(12):1934-6. doi: 10.1136/ard.2009.111807.
引用本文的文献
1
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Progress in Small Molecule Drug Development.非甾体抗炎药（NSAIDs）：小分子药物研发进展
Pharmaceuticals (Basel). 2010 May 14;3(5):1530-1549. doi: 10.3390/ph3051530.
2
UP446, analgesic and anti-inflammatory botanical composition.UP446，一种具有止痛和抗炎作用的植物成分。
Pharmacognosy Res. 2013 Jul;5(3):139-45. doi: 10.4103/0974-8490.112406.
3
Neutralizing endogenous chemokines with small molecules. Principles and potential therapeutic applications.用小分子中和内源性趋化因子。原理和潜在的治疗应用。
Pharmacol Ther. 2010 Apr;126(1):39-55. doi: 10.1016/j.pharmthera.2009.12.003. Epub 2010 Feb 1.
4
The p38 mitogen-activated protein kinase signaling cascade in CD4 T cells.CD4 T细胞中的p38丝裂原活化蛋白激酶信号级联反应。
Arthritis Res Ther. 2006;8(2):205. doi: 10.1186/ar1905. Epub 2006 Feb 17.
本文引用的文献
1
Heterogeneous requirement of IkappaB kinase 2 for inflammatory cytokine and matrix metalloproteinase production in rheumatoid arthritis: implications for therapy.类风湿关节炎中IκB激酶2对炎性细胞因子和基质金属蛋白酶产生的异质性需求：对治疗的启示
Arthritis Rheum. 2003 Jul;48(7):1901-12. doi: 10.1002/art.11044.
2
Bruton's tyrosine kinase is required for lipopolysaccharide-induced tumor necrosis factor alpha production.布鲁顿酪氨酸激酶是脂多糖诱导肿瘤坏死因子α产生所必需的。
J Exp Med. 2003 Jun 16;197(12):1603-11. doi: 10.1084/jem.20021845.
3
The specificities of protein kinase inhibitors: an update.蛋白激酶抑制剂的特异性：最新进展
Biochem J. 2003 Apr 1;371(Pt 1):199-204. doi: 10.1042/BJ20021535.
4
Anti-TNF therapy for other inflammatory conditions.用于其他炎症性疾病的抗 TNF 治疗。
Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S146-51.
5
Ikappa B kinase 2 but not NF-kappa B-inducing kinase is essential for effective DC antigen presentation in the allogeneic mixed lymphocyte reaction.IκB激酶2而非NF-κB诱导激酶对于同种异体混合淋巴细胞反应中有效的树突状细胞抗原呈递至关重要。
Blood. 2003 Feb 1;101(3):983-91. doi: 10.1182/blood-2002-06-1835. Epub 2002 Sep 19.
6
Cytokines and anti-cytokine biologicals in autoimmunity: present and future.自身免疫中的细胞因子和抗细胞因子生物制剂：现状与未来。
Cytokine Growth Factor Rev. 2002 Aug-Oct;13(4-5):299-313. doi: 10.1016/s1359-6101(02)00018-7.
7
TNF-R1 signaling: a beautiful pathway.肿瘤坏死因子受体1信号传导：一条美妙的信号通路。
Science. 2002 May 31;296(5573):1634-5. doi: 10.1126/science.1071924.
8
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.英夫利昔单抗治疗活动性强直性脊柱炎：一项随机对照多中心试验。
Lancet. 2002 Apr 6;359(9313):1187-93. doi: 10.1016/s0140-6736(02)08215-6.
9
Nuclear factor-kappaB activation in alveolar macrophages requires IkappaB kinase-beta, but not nuclear factor-kappaB inducing kinase.肺泡巨噬细胞中核因子-κB的激活需要IκB激酶-β，但不需要核因子-κB诱导激酶。
Am J Respir Crit Care Med. 2002 Apr 1;165(7):996-1004. doi: 10.1164/ajrccm.165.7.2107058.
10
Fomivirsen for the treatment of cytomegalovirus retinitis.膦甲酸钠用于治疗巨细胞病毒性视网膜炎。
Am J Ophthalmol. 2002 Apr;133(4):552-6. doi: 10.1016/s0002-9394(02)01325-9.
Zotero 插件